WT1-targeted autologous dendritic cell vaccine (University of Antwerp)

N/A

Report date: 2023/09/05 20:09:53

Base Information

Drug NameWT1-targeted autologous dendritic cell vaccine (University of Antwerp)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionWilms' Tumour 1 (WT1)-directed cytolytic effects

TargetsWilms' Tumour 1

Therapy Area/IndicationsColorectal NeoplasmsBreast NeoplasmsCarcinoma, Renal Cell +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Antwerp Antwerp University Hospital

China Registration ClassN/A

Develop Information

Active CompaniesAntwerp University Hospital

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsColorectal NeoplasmsBreast NeoplasmsCarcinoma, Renal Cell +[6]

Other Information

ATC CodeN/A